What's new in dystonia?

Current Neurology and Neuroscience Reports

Volumn 9, Issue 4, 2009, Pages 278-284

  Shanker, Vicki ^a   Bressman, Susan B ^b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; DOPAMINE; EPSILON SARCOGLYCAN; GAG PROTEIN; GENE PRODUCT; GUANOSINE TRIPHOSPHATE CYCLOHYDROLASE I; KAINIC ACID; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PROTEIN DYT1; PROTEIN DYT13; PROTEIN DYT6; PROTEIN THAP1; QUETIAPINE; RISPERIDONE; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN; ZIPRASIDONE; ANTIPARKINSON AGENT; APOPTOSIS REGULATORY PROTEIN; CHAPERONE; DNA BINDING PROTEIN; NUCLEAR PROTEIN; THAP1 PROTEIN, HUMAN; TOR1A PROTEIN, HUMAN;

BASAL GANGLION; BLEPHAROSPASM; BRAIN DEPTH STIMULATION; CEREBELLUM DISEASE; CERVICAL DYSTONIA; CLINICAL TRIAL; COFFEE; DELIRIUM; DEPRESSION; DISEASE CLASSIFICATION; DISEASE DURATION; DOPAMINE RELEASE; DYSPHAGIA; DYSTONIA; ESSENTIAL TREMOR; EXTRAPYRAMIDAL SYNDROME; FOCAL DYSTONIA; GENE FUNCTION; GENE MUTATION; GENERALIZED DYSTONIA; GENETIC VARIABILITY; GLOBUS PALLIDUS; HUMAN; HYPERKINESIA; HYPOMANIA; INJECTION SITE PAIN; MOTOR DYSFUNCTION; MYOCLONUS DYSTONIA; NEUROPATHOLOGY; NONHUMAN; ONSET AGE; PARKINSON DISEASE; PARKINSONISM; QUALITY OF LIFE; RATING SCALE; REVIEW; SEGAWA DISEASE; SEX DIFFERENCE; SUICIDE; TORSION DYSTONIA; TREATMENT RESPONSE; XEROSTOMIA; DIFFERENTIAL DIAGNOSIS; GENETICS; HOSPITALIZATION; METABOLISM; PATHOPHYSIOLOGY;

AGE OF ONSET; ANTI-DYSKINESIA AGENTS; APOPTOSIS REGULATORY PROTEINS; BOTULINUM TOXINS; DEEP BRAIN STIMULATION; DIAGNOSIS, DIFFERENTIAL; DNA-BINDING PROTEINS; DYSTONIA; HUMANS; MOLECULAR CHAPERONES; NUCLEAR PROTEINS; SEVERITY OF ILLNESS INDEX;

EID: 67651230842     PISSN: 15284042     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11910-009-0042-5     Document Type: Review

References (55)

1. Neychev V, Fan X, Mitev V, et al.: The basal ganglia and cerebellum interact in the expression of dystonic movement. Brain 2008, 131:2499-2509.
2. Teo J, van de Warrenburg B, Schneider S, et al.: Neurophysiological evidence for cerebellar dysfunction in primary focal dystonia. J Neurol Neurosurg Psychiatry 2009, 80:80-83.
3. Brighina F, Romano M, Giglia G, et al.: Effects of cerebellar TMS on motor cortex of patients with focal dystonia: A preliminary report. Exp Brain Res 2009, 192:651-656.
4. Carbon M, Ghilardi M, Argyelan M, et al.: Increased cerebellar activation during sequence learning in DYT1 carriers: An equiperformance study. Brain 2008, 131:146-154.
5. Hanajima R, Nomura Y, Segawa M, et al.: Intracortical inhibition of the motor cortex in Segawa disease (DYT5). Neurology 2007, 68:1039-1044.
6. Li J, Cunic D, Paradiso G, et al.: Electrophysiological features of myoclonus-dystonia. Mov Disord 2008, 23:2055-2061.
7. Marelli C, Canafoglia L, Zibordi F, et al.: A neurophysiological study of myoclonus in patients with DYT11 myoclonus-dystonia syndrome. Mov Disord 2008, 23:2041-2048.
8. Ochudlo S, Drzyzga K, Drzyzga LR, et al.: Various patterns of gestes antagonistes in cervical dystonia. Parkinsonism Relat Disord 2007, 13:417-420.
9. Miller K, Okun M, Fernandez H, et al.: Depression symptoms in movement disorders: Comparing Parkinson's disease, dystonia, and essential tremor. Mov Disord 2007, 22:666-672.
10. Lewis L, Butler A, Jahanshahi M: Depression in focal, segmental and generalized dystonia. J Neurol 2008, 255:1750-1755.
11. Schwingenschuh P, Pont-Sunyer C, Surtees R, et al.: Psychogenic movement disorders in children: A report of 15 cases and a review of the literature. Mov Disord 2008, 23:1882-1888.
12. Ferrara J, Jankovic J: Psychogenic movement disorders in children. Mov Disord 2008, 23:1875-1881.
13. de Vries P, Leenders K, van der Hoeven J, et al.: Abnormal surface EMG during clinically normal wrist movement in cervical dystonia. Eur J Neurol 2007, 14:1244-1250.
14. Krystkowiak P, du Montcel S, Vercueil L, et al.: Reliability of the Burke-Fahn-Marsden scale in a multicenter trial for dystonia. Mov Disord 2007, 22:685-689.
15. Kägi G, Schwingenschuh P, Bhatia K: Arm swing is reduced in idiopathic cervical dystonia. Mov Disord 2008, 23:1784-1787.
16. Zirn B, Grundmann K, Huppke P, et al.: Novel TOR1A mutation p.Arg288Gln in early-onset dystonia (DYT1). J Neurol Neurosurg Psychiatry 2008, 79:1327-1330.
17. Risch NJ, Bressman SB, Senthil G, et al.: Intragenic cis and trans modification of genetic susceptibility in DYT1 torsion dystonia. Am J Hum Genet 2007, 80:1188-1193.
18. Saunders-Pullman R, Raymond D, Senthil G, et al.: Narrowing the DYT6 dystonia region and evidence for locus heterogeneity in the Amish-Mennonites. Am J Med Genet A 2007, 143A:2098-2105.
19. Fuchs T, Gavarini S, Saunders-Pullman R, et al.: Mutations in the THAP1 gene are responsible for DYT6 primary torsion dystonia. Nat Genet 2009, 41:286-288.
20. Chouery E, Kfoury J, Delague V, et al.: A novel locus for autosomal recessive primary torsion dystonia (DYT17) maps to 20p11.22-q13.12. Neurogenetics 2008, 9:287-293.
21. Koukouni V, Martino D, Arabia G, et al.: The entity of young onset primary cervical dystonia. Mov Disord 2007, 22:843-847.
22. Foulks G: The correlation between the tear film lipid layer and dry eye disease. Surv Ophthalmol 2007, 52:369-374.
23. Nicoletti AG, Zacharias LC, Susanna R Jr, Matayoshi S: Patients with essential blepharospasm and glaucoma: Case reports. Arq Bras Oftalmol 2008, 71:747-751.
24. Defazio G, Martino D, Abbruzzese G, et al.: Influence of coffee drinking and cigarette smoking on the risk of primary late onset blepharospasm: evidence from a multicentre case control study. J Neurol Neurosurg Psychiatry 2007, 78:877-879.
25. Papapetropoulos S, Baez S, Zitser J, et al.: Retrocollis: classification, clinical phenotype, treatment outcomes and risk factors. Eur Neurol 2008, 59:71-75.
26. Contarino M, Berger-Plantinga E, Foncke E, et al.: Clinical and genetic characterization of a large Dutch family with primary focal dystonia. Mov Disord 2008, 23:1998-2003.
27. Zirn B, Steinberger D, Troidl C, et al.: Frequency of GCH1 deletions in Dopa-responsive dystonia. J Neurol Neurosurg Psychiatry 2008, 79:183-186.
28. Wider C, Melquist S, Hauf M, et al.: Study of a Swiss dopa-responsive dystonia family with a deletion in GCH1: Redefining DYT14 as DYT5. Neurology 2008, 70:1377-1383.
29. Brashear A, Dobyns W, de Carvalho Aguiar P, et al.: The phenotypic spectrum of rapid-onset dystonia-parkinsonism (RDP) and mutations in the ATP1A3 gene. Brain 2007, 130:828-835.
30. Ritz K, GerritC M, Foncke E, et al.: Myoclonus-dystonia: clinical and genetic evaluation of a large cohort. J Neurol Neurosurg Psychiatry 2008 Dec 15 (Epub ahead of print).
31. Nardocci N, Zorzi G, Barzaghi C, et al.: Myoclonus-dystonia syndrome: clinical presentation, disease course, and genetic features in 11 families. Mov Disord 2008, 23:28-34.
32. Guettard E, Portnoi M, Lohmann-Hedrich K, et al.: Myoclonus-dystonia due to maternal uniparental disomy. Arch Neurol 2008, 65:1380-1385.
33. Raymond D, Saunders-Pullman R, de Carvalho Aguiar P, et al.: Phenotypic spectrum and sex effects in eleven myoclonus-dystonia families with epsilon-sarcoglycan mutations. Mov Disord 2008, 23:588-592.
34. Luciano M, Ozelius L, Sims K, et al.: Responsiveness to levodopa in epsilon-sarcoglycan deletions. Mov Disord 2009, 24:425-428.
35. Hess C, Raymond D, Aguiar PC, et al.: Myoclonus-dystonia, obsessive-compulsive disorder, and alcohol dependence in SGCE mutation carriers. Neurology 2007, 68: 522-524.
36. Han F, Racacho L, Lang A, et al.: Refinement of the DYT15 locus in myoclonus dystonia. Mov Disord 2007, 22:888-892.
37. Asmus F, Langseth A, Doherty E, et al.: "Jerky" dystonia in children: Spectrum of phenotypes and genetic testing. Mov Disord 2009, 24:702-709.
38. Miller del D, Caroff SN, Davis SM, et al.: Extrapyramidal side-effects of antipsychotics in a randomised trial. Br J Psychiatry 2008, 193:279-288.
39. SimpsoB D, Blitzer A, Brashear A, et al.: Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008, 70:1699-1706.
40. Pappert E, Germanson T: Botulinum toxin type B vs. type A in toxin-naìve patients with cervical dystonia: Randomized, double-blind, noninferiority trial. Mov Disord 2008, 23:510-517.
41. Chapman MA, Barron R, Tanis D, et al.: Comparison of botulinum neurotoxin preparations for the treatment of cervical dystonia. Clin Ther 2007, 29:1323-1337.
42. Dressler D, Bigalke H: Botulinum toxin type B de novo therapy of cervical dystonia: Frequency of antibody induced therapy failure. J Neurol 2005, 252:904-907.
43. Mueller J: Re: Botulinum toxin type B vs. type a in toxin-naìve patients with cervical dystonia: Randomized, double-blind, noninferiority trial. Mov Disord 2008 Oct 21 (Epub ahead of print).
44. Kranz G, Sycha T, Voller B, et al.: Neutralizing antibodies in dystonic patients who still respond well to botulinum toxin type A. Neurology 2008, 70:133-136.
45. Vidailhet M, Vercueil L, Houeto J, et al.: Bilateral, pallidal, deep-brain stimulation in primary generalised dystonia: A prospective 3 year follow-up study. Lancet Neurol 2007, 6:223-229.
46. Isaias I, Alterman R, Tagliati M: Outcome predictors of pallidal stimulation in patients with primary dystonia: The role of disease duration. Brain 2008, 131:1895-1902.
47. Pretto T, Dalvi A, Kang U, et al.: A prospective blinded evaluation of deep brain stimulation for the treatment of secondary dystonia and primary torticollis syndromes. J Neurosurg 2008, 109:405-409.
48. Moro E, Piboolnurak P, Arenovich T, et al.: Pallidal stimulation in cervical dystonia: Clinical implications of acute changes in stimulation parameters. Eur J Neurol 2009, 16:506-512.
49. Alterman R, Miravite J, Weisz D, et al.: Sixty hertz pallidal deep brain stimulation for primary torsion dystonia. Neurology 2007, 69:681-688.
50. Blomstedt P, Fytagoridis A, Tisch S: Deep brain stimulation of the posterior subthalamic area in the treatment of tremor. Acta Neurochir (Wien) 2009, 151:31-36.
51. Moll C, Hamel W, Ostertag C, et al.: Subthalamotomy in cervical dystonia: A case study of lesion location and clinical outcome. Mov Disord 2008, 23:1751-1756.
52. Kim M, Jeon S, Yoo H, et al.: Effect of thalamotomy on focal hand dystonia in a family with DYT1 mutation. Mov Disord 2008, 23:2251-2255.
53. Kuncel AM, Turner DA, Ozelius LJ, et al.: Myoclonus and tremor response to thalamic deep brain stimulation parameters in a patient with inherited myoclonus-dystonia syndrome. Clin Neurol Neurosurg 2009, 111:303-306.
54. Appleby B, Duggan P, Regenberg A, et al.: Psychiatric and neuropsychiatric adverse events associated with deep brain stimulation: a meta-analysis of ten years' experience. Mov Disord 2007, 22:1722-1728.
55. Mueller J, Skogseid I, Benecke R, et al.: Pallidal deep brain stimulation improves quality of life in segmental and generalized dystonia: Results from a prospective, randomized sham-controlled trial. Mov Disord 2008, 23:131-134.